(CercleFinance.com) – GenSight Biologics shares soared more than 20% on Wednesday morning on the Paris Stock Exchange after the biopharmaceutical company reported data collected over five years for its treatment of Leber’s hereditary optic neuropathy (LHON), a rare disease that can lead to blindness.
Based on these findings, patients treated with Lumevoq continued to experience marked improvement in their vision five years after a single injection of the gene therapy.
Compared to the evolution of vision observed in untreated patients, these results differ ‘significantly’ compared to the natural history, underlines the company.
In detail, 71% of the subjects thus obtained a ‘clinically relevant’ recovery of their vision, while 80.7% of them could read at least five ETDRS letters at a distance of one meter.
This follow-up study included 62 subjects, 55 of whom completed the study.
As a reminder, the review of Lumevoq’s European Marketing Authorization Application (MA) is ongoing, with a CHMP decision expected in the third quarter of 2023.
The commercial launch of the product is planned following the approval, i.e. by the end of 2023.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
